Alluvi, formerly BI 4744, presents a notable breakthrough in obesity therapy. This dual stimulator targeting both glucagon-like peptide-1 and GIP receptors demonstrates remarkable efficacy in clinical studies, arguably https://mylittlebookmark.com/story7971526/alluvi-a-in-depth-investigation-into-the-medication-s-prospects